CIK 0001231457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- 4 Open-market buy Director bought 2,500 shares
- 4 Open-market buy Director bought 8,000 shares
- 4 Open-market buy VP, Clinical Trial Operations bought 2,500 shares
- 4 Open-market buy President and CEO bought 200,000 shares
- 4 Open-market buy Head of Regulatory bought 1,250 shares
- 4 Open-market buy General Counsel bought 10,000 shares
- 4 Open-market buy Chief Financial Officer bought 31,250 shares
- 4 Open-market sale 10% owner sold 35,966 shares at an average $3.62 ($130,377)
- 4 Open-market sale 10% owner sold 19,944 shares at an average $3.78 ($75,300)
- 4 Open-market sale 10% owner sold 59,999 shares at an average $3.23 ($193,934)
- 4 Open-market sale 10% owner sold 44,395 shares at an average $3.51 ($155,647)
- 4 Open-market sale 10% owner sold 71,420 shares at an average $3.59 ($256,227)
- 4 Open-market sale VP, Clinical Trial Operations sold 32,535 shares at an average $13.16 ($428,180)
- 4 Open-market sale Director sold 9,000 shares at an average $13.22 ($118,969)
- 4 Open-market sale Director sold 9,000 shares at an average $13.38 ($120,387)
- 4 Open-market sale VP, Clinical Trial Operations sold 36,800 shares at $11.85 ($435,995)
- 4 Open-market sale VP, Clinical Trial Operations sold 18,665 shares at $10.26 ($191,555)
- 4 Open-market sale VP, Clinical Trial Operations sold 18,135 shares at an average $11.60 ($210,431)
- 4 Open-market sale 10% owner sold 5,704 shares at $19.40 ($110,638)
- 4 Open-market sale 10% owner sold 49,987 shares at $19.97 ($998,365)
Page 6 of 10 · 190 filings